KemPharm, Inc. announced changes to its Board of Directors (Board) and executive leadership team as part of the Company's ongoing business transformation initiatives. Effective immediately, Matthew R. Plooster, who has been serving as an independent member of the Board of Directors, has been appointed to serve as Chairman of the Board of Directors. Richard W. Pascoe, who has been serving as Executive Chairman, will transition into the role of and remains a member of the Board of Directors.

Travis C. Mickle, Ph.D., who is co-founder and has been serving as President and CEO, will transition to the role of President and will also remain a member of the Board of Directors until the Company's 2023 Annual Meeting of stockholders. Thereafter, Dr. Mickle will continue to support the Company's pipeline build and the planned resubmission of the arimoclomol New Drug Application as a scientific advisor. Additionally, Joshua Schafer has been appointed to the newly created role of Chief Commercial Officer and Executive Vice President of Business Development.

The Board believes that these leadership changes are an important component of strategic transformation into a leading rare disease company, build upon the strengths of the senior leadership team and have the potential to further enable the team to achieve the Company's key objectives, which include securing regulatory approval for its pipeline assets, building top-tier commercial capabilities, and enhancing the Company's development pipeline through targeted business development transactions. Joshua Schafer brings to KemPharm over 25 years of pharmaceutical commercial, new product development and merger and acquisition (M&A) experience. Mr. Schafer previously served as General Manager of the Autoimmune and Rare Disease business at Mallinckrodt Pharmaceuticals, and prior to that, he served as Chief Strategy and Business Officer.

During his professional career, he has successfully led over $16 billion in aggregate M&A transactions. Prior to Mallinckrodt, Mr. Schafer served as Vice President and Oncology Therapeutic Area Head, Global Marketing and Strategy at Astellas Pharmaceuticals, where he was responsible for building the company's global oncology franchise, and also held senior roles at Takeda Pharmaceuticals, Accenture, G. D. Searle & Co. and Cognia Corporation.

Mr. Schafer currently serves as a Board member of Pharnext SA and Shuttle Pharmaceuticals. He received his B.A. in Biology and German at the University of Notre Dame, and both an M.S. in Biotechnology and an M.B.A. from Northwestern University. In connection with Mr. Schafer's appointment, on January 6, 2023, the Compensation Committee of the Company's Board of Directors approved a grant, effective January 9, 2023, to Mr. Schafer of an option to purchase 300,000 shares of the Company's common stock.

The stock option has an exercise price per share equal to the closing trading price of the Company's common stock on January 9, 2023. The option will vest in four equal annual installments, with the first such installment occurring on January 9, 2024, subject to Mr. Schafer's continued employment on each vesting date. The award was granted under the KemPharm 2023 Employment Inducement Award Plan, which was approved by the Company's Board of Directors in January 2023 under Rule 5635(c)(4) of the Nasdaq Listing Rules for equity grants to induce new employees to enter into employment with the Company.